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Abstract
Accurate determination of circadian phase is necessary for research and clinical purposes because of the influence of the
master circadian pacemaker on multiple physiologic functions. Melatonin is presently the most accurate marker of the
activity of the human circadian pacemaker. Current methods of analyzing the plasma melatonin rhythm can be grouped
into three categories: curve-fitting, threshold-based and physiologically-based linear differential equations. To determine
which method provides the most accurate assessment of circadian phase, we compared the ability to fit the data and the
variability of phase estimates for seventeen different markers of melatonin phase derived from these methodological
categories. We used data from three experimental conditions under which circadian rhythms - and therefore calculated
melatonin phase - were expected to remain constant or progress uniformly. Melatonin profiles from older subjects and
subjects with lower melatonin amplitude were less likely to be fit by all analysis methods. When circadian drift over multiple
study days was algebraically removed, there were no significant differences between analysis methods of melatonin onsets
(P=0.57), but there were significant differences between those of melatonin offsets (P,0.0001). For a subset of phase
assessment methods, we also examined the effects of data loss on variability of phase estimates by systematically removing
data in 2-hour segments. Data loss near onset of melatonin secretion differentially affected phase estimates from the
methods, with some methods incorrectly assigning phases too early while other methods assigning phases too late; missing
data at other times did not affect analyses of the melatonin profile. We conclude that melatonin data set characteristics,
including amplitude and completeness of data collection, differentially affect the results depending on the melatonin
analysis method used.
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Introduction
Circadian phase is a major determinant of the time course and
level of sleepiness, cognitive performance, many hormone
concentrations and multiple other physiologic functions. Accurate
measurement of circadian phase is also vital for the correct
diagnosis and appropriate treatment for circadian rhythm sleep
disorders. Since circadian phase of the suprachiasmatic nucleus
(SCN), the site of the mammalian circadian pacemaker, cannot be
measured directly in humans, outputs of the clock must be used as
markers of the circadian system. Commonly used circadian phase
markers include core body temperature (CBT), cortisol, and
melatonin. A critical factor in choosing an appropriate marker for
assessing circadian phase, either for clinical applications or
research, is the influence of exogenous factors that can directly
mask, or obscure, the underlying endogenous circadian rhythm of
the output marker. In inpatient studies in which these exogenous
factors are controlled or eliminated, melatonin-based phase
assessments produce the least variable estimates of circadian
phase [1] when assessed under dim light conditions. Compared to
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33836CBT and cortisol rhythms, the melatonin rhythm is less influenced
by changes in sleep-wake state, exercise or mood [2], although the
effects of posture remain controversial [3,4]. Concentrations of
melatonin or its metabolites can be easily obtained from blood,
saliva, or urine specimens [4,5,6,7].
The synthesis and daily rhythm of melatonin secretion is
regulated by the SCN. In entrained individuals, melatonin levels
remain low during the day with melatonin onset occurring
,2 hours prior to bedtime, and peak near the middle of the
habitual nighttime, 2 to 3 hours before the core body temperature
(CBT) nadir [8]. Under non-dim light conditions, light exposure in
the evening and night suppresses the endogenous onset of
melatonin secretion [9]. The pathway for inhibition of melatonin
secretion in response to input occurs via the retino-hypothalamic
tract (RHT), the pathway through which photic information
travels from the eye to the SCN. The RHT remains intact in some
totally visually blind people and allows them to entrain to the 24-
hour day and demonstrate melatonin suppression even in the
absence of conscious vision [10,11,12]. Conversely, in some
visually intact individuals with spinal cord injury there is no
rhythmic melatonin secretion, presumably due to damage to the
pathway from the SCN to the pineal gland [13,14]. Thus, the
measurement of melatonin levels can provide information on the
status of the pathway from the eye to the SCN and to the pineal, as
well as provide information on circadian phase and amplitude in
individuals in whom this pathway is intact.
Several methods have been developed to analyze the phase and
amplitude of the circadian melatonin rhythm. These methods
usually calculate the ‘onset’, midpoint and ‘offset’ relative to a
threshold of an assumed symmetrical melatonin secretion profile,
although onset and cessation of actual synthesis are more relevant
physiologically [15]. Most of these methods fall into one of three
categories in which phase is determined: (i) by fitting a curve to the
melatonin profile, usually a sinusoidal-based function; (ii) by
determining when melatonin levels cross either an absolute
concentration threshold, or an individualized threshold; or (iii)
by using a physiologically-based linear differential equation model
to estimate the onset of melatonin secretion, the cessation of
synthesis, the amplitude of the melatonin rhythm, and rates of
infusion and clearance of melatonin from the plasma or saliva.
The first two categories of methods assume that: (i) the shape of
the melatonin profile is appropriate for the analysis method,
including a monotonic rise; (ii) the shape of the melatonin profile
does not change significantly from day-to-day or under different
conditions; (iii) the amplitude of an individual’s melatonin rhythm is
sufficiently great to allow for curve-fitting or determination of a
threshold; and (iv) the melatonin rhythm has a mainly symmetrical
profile with a single peak (for pure sinusoidal-based or midpoint-
based methods). There is ample evidence that such assumptions are
not met in many cases. Additionally, inter-individual variations in
melatonin profiles may affect phase estimates derived from some
threshold-based methods (e.g. 10 pg/ml), although it is not known if
the physiologicallysignificant onsetconcentration may differ among
individuals. Furthermore, although threshold-based methods do not
require collecting the full 24-hr profile (e.g. if computing only time
ofcrossing of10 pg/ml),they areextremely sensitivetomissing data
around the threshold crossing time(s). Physiologically-based meth-
ods (e.g., linear differential equations based on the physiology such
as [15]), meanwhile, can provide an estimate of pineal activity, and
therefore the amplitude and rates of infusion and clearance in the
plasma can be computed; these two physiologic variables cannot be
determined from curve-fitting and threshold methods.
Several reports have compared different methods of analyzing
melatonin, with an emphasis on the fitting of the data, rather than
the use of the method in computing circadian phase. In testing
their physiologically-based linear differential equation model,
Brown et al. [15] compared values generated by their model with
selected values from other methods, including one threshold
crossing (Dim Light Melatonin Onset (DLMO) – interpolated
crossing) and one 3-harmonic curve-fitting method. Van Someren
and Nagtegaal [16] compared the analysis of salivary melatonin
using three curve-fitting models, which included a skewed baseline
cosine function, a bimodal cosine function, and a combination of
these two into a bimodal skewed cosine function, with analysis
from several curve-fitting and interpolating methods. These new
curve-fitting models, which accounted for differences in steepness
of rising and falling portions of the melatonin profile (skewed) and
variations in melatonin peak (such as broader or flatter or even two
peaks (bimodal)), were found not only to fit the data better than
previous models but to be robust even after data points were
removed to simulate missing data. They also evaluated the
robustness of phase estimates in the presence of systematically
added noise; this noise generated approximately 10 minutes of
deviation in the phase from the original estimates. The focus of
their report, however, was the fit of the data and not whether
phase markers derived from different fitting methods differed
significantly from one another within a subject across days or
could be used in different experimental conditions, with decreased
melatonin amplitude, or with different subject populations.
Previous studies assessing melatonin as a marker of human
circadian phase have not addressed issues related to its reliability
under different experimental circumstances. There are at least
three areas of concern: (i) phase assessment methods from more
than one study condition/design have not been compared to each
other, raising concerns about the generalizability of the findings
[1,17]; (ii) the effects of removing data on phase assessment
variability have not been systematically examined, although, in the
case of missing or noisy data, fitted methods using all data points
would be expected to provide more accurate results than those
methods relying on interpolation, which utilize fewer points [1,16];
and (iii) correlates of melatonin profiles that could be fit by one but
not another analysis method. This report addresses all three
concerns.
We compared curve-fitting, threshold, and linear differential
equation mathematical model (‘‘physiological’’) methods of
analyzing melatonin data. The variabilities of these methods on
circadian phase estimates of data collected from multiple
protocols, with different melatonin amplitudes, and from healthy
but mixed populations (sighted and blind, young and older, male
and female) were quantified. To test the robustness of different
circadian phase assessment methods, we explored the time-
dependent effects of missing data on phase estimates by removing
data at different time intervals in the melatonin profile.
Methods
Data sets
All studies were conducted in the Brigham and Women’s
Hospital inpatient General Clinical Research Center or Center for
Clinical Investigation, using techniques reported elsewhere (see
below). All studies were approved by the Partners Healthcare
Human Subjects Committee and all subjects gave written
informed consent. Procedures were in compliance with U.S.
Health Insurance Portability and Accountability Act regulations
and the Declaration of Helsinki. All subjects were healthy
according to medical history, physical exam, blood chemistries,
psychological screening tests and visits with a clinical psychologist.
Subjects in Studies 1–5 were not color blind; subjects in Study 6
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met all other criteria. Subjects were not using any prescription or
non-prescription medications, had regular sleep/wake schedules,
and had not used caffeine or tobacco for at least the week prior to
entry to the inpatient portion of the study.
Three non-overlapping ,24-h days of data were used from
each subject. These three days were chosen to be under dim light
conditions so that the endogenous circadian pacemaker would
expect to drift uniformly at its endogenous period and therefore
the variability of the markers could be tested. Complete data sets
were defined as three ,24-h days of data in which there were less
than 2 consecutive hours of missing data and less than 6 total
hours of missing data per 24-hr. Blood samples were drawn every
30–60 minutes in all studies. For all studies, melatonin was assayed
by RIA.
Study 1. [18] Data were available for thirteen subjects aged
17–29 years who participated in a protocol that began with 3
baseline days (8 h of sleep and 16 h of wake) followed by a
constant routine (CR, an extended period of enforced wakefulness
in a semi-recumbent position with frequent small meals [19] that
lasted 26–33 hr. There were then 3 days on an inverted sleep-
wake schedule with 5 h of darkness centered in the middle of the
inverted wake episode, a second CR, 3 more days with darkness
exposure and a final CR. Light levels were 90 lux (approximately
90 lux measured at 540 from the floor and maximum 150 lux
measured at 720 from the floor in the horizontal angle from
anywhere in the room) for waking baseline days, 4 lux
(approximately 3.3 lux measured at 540 from the floor and
maximum 15 lux measured at 720 from the floor in the horizontal
angle from anywhere in the room) during the CR and intervention
days, and 0 lux for all sleep episodes and the darkness exposures.
Data from the three CRs were used.
Study 2. (Santhi et al., unpublished data). Data were available
from six subjects aged 19–30 years who participated in a protocol
that began with 3 baseline days followed by a 50-h CR. Light
levels during baseline days were 90 lux (defined as in Study 1) for
baseline until the last 8 hours of the wake episode before the CR,
3 lux (approximately 1.8 lux measured at 540 from the floor and
maximum 8 lux measured at 720 from the floor in the horizontal
angle from anywhere in the room) during the last five hours of the
wake episode before the CR and during the CR, and 0 lux during
sleep. The three 24 hrs of data were from the 24 hours
immediately before the CR and the two 24-h periods during the
50-h CR.
Study 3. [9,20]. Data were available from 20 subjects aged
19–28 years who participated in a protocol that began with three
baseline days followed by a 50-h CR. Light levels during the
baseline day were 90 lux (defined as in Study 1) until the last
8 hours of the wake episode before the CR, 3 lux (defined as in
Study 2) for the remainder of the study except for during sleep
episodes when they were 0 lux. The three 24 hrs of data were
from the 24 hours immediately before the CR and the two 24-h
periods during the 50-h CR.
Study 4. [21]. Data were available from 20 healthy older
subjects aged 65–81 years and 16 younger subjects aged 19–29
years who participated in a protocol that began with 3 baseline
days followed by a CR. Light levels were 90 lux (defined as in
Study 1) for waking baseline days, 4 lux (defined as in Study 1)
during the CR and intervention days, and 0 lux for all sleep
episodes. The three 24 hrs of data were from the 24 hours
immediately before the CR and the two 24-h periods during the
CR.
Study 5. [22]. Data were available from 12 subjects aged 21–
32 years who participated in a protocol that included a forced
desynchrony segment with 28-h ‘‘days’’. Light levels were 4 lux
(defined as in Study 1) during wake episodes and 0 lux during
sleep episodes. Data were from the beginning of the forced
desynchrony segment, with three consecutive 24-h days for all but
one subject, in whom the data were from 4 consecutive 24-h days
because of missing data on one of the intermediate days.
Study 6. [23] Data were collected from 11 visually blind (i.e.,
no conscious light perception) subjects, aged 27–68 years, who
participated in a 38-day inpatient protocol that included a forced
desynchrony segment (24 28-h ‘‘days’’). Light levels were 4 lux
(defined as in Study 1) during 18.67-h scheduled wake episodes
and 0 lux during 9.33-h scheduled sleep episodes. Data from the
first three consecutive 24-h days of the forced desynchrony
segment for all but one subject, in whom the 3 data points were
obtained from 4 consecutive days, due to missing data on one of
the days.
Note that while the actual light levels used for these studies did
not change, the descriptive terms describing light levels changed
between studies conducted before and after 2004; the current
nomenclature is used in this report for all studies. Further details
about the lighting used in these studies are reported in the original
publications.
Melatonin analysis methods
Six methods were used for the analysis of the melatonin data:
two threshold-based methods, three curve fitting methods, and a
physiologically-based differential equation model (Figure 1); these
yielded a total of 17 circadian phase markers. In Table 1 we
provide a description of each marker with abbreviations used
throughout the text.
In this analysis, ‘‘threshold-based methods’’ refer to methods of
melatonin analysis that depend on the crossing of a pre-
determined melatonin concentration. The threshold-based meth-
ods compared here included thresholds based on the dim light
melatonin onset (DLMO) and from the 24-h mean of the
melatonin profile. DLMO methods included (i) DLMOinterpolated,
the time when the plasma melatonin concentrations crossed the
threshold of 10 pg/ml (43.08 pmol/L) as determined by linear
interpolation between the measured values flanking this value (ii)
DLMOpost-threshold, the blood sample time at which the first
measured melatonin value exceeded the 10 pg/ml threshold value
[7]; and (iii) the interpolated time at which melatonin levels
exceeded DLMOn 25% or fell below DLMOff 25% for at least
two consecutive data points using a threshold of 25% of the fitted
peak-to-trough melatonin concentrations computed using a non-
orthogonal spectral analysis (NOSA) [24]. The fitted peak
melatonin concentration to determine the 25% level was
calculated from the melatonin profile on CR in Studies 1 to 4
(excluding first 5-h of CR) and the first forced desynchrony day
(Studies 5 and 6). In total, four phase markers were derived from
the DLMO methods: three onsets (DLMOinterpolated, DLMO-
post-threshold, DLMOn25%) and one offset (DLMOff25%).
DLMOinterpolated and DLMOpost-threshold do not require a
full melatonin profile to compute. DLMOn25% and DLMOff25%
require at least one 24-h profile (preferably during a constant
routine condition) to determine the 25% threshold level.
Estimates based on the mean of the 24-h melatonin profile
include the 24hUpcross, 24hMidpoint and 24hDowncross. For
each 24-h segment of data the mean value of the melatonin
concentration was computed and used as the threshold. The
24hUpcross was calculated by linear interpolation as the time at
which melatonin concentration crossed this threshold value on the
rising portion of the curve. The 24hDowncross was calculated in a
similar fashion on the falling portion of the curve. The
Conditions Influencing Melatonin Circadian Phase
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e33836Figure 1. Phase Markers from Six Method Types of Analyzing Melatonin Data. Diagram of the phase markers from six methods used to
analyze a single melatonin profile (subject 1849v). The upper panel includes the assayed melatonin values, plotted as melatonin concentration (pmol/
L). The lower panel groups the various phase markers by method and indicates their position with respect to upper panel. Fourier-based analysis
methods F(2) and F(3) have been combined in this diagram because of their similarity.
doi:10.1371/journal.pone.0033836.g001
Table 1. Description of melatonin phase estimate methods and abbreviations used throughout text. DLMO refers to Dim Light
Melatonin Onset.
Method Abbreviation Number (%) of profiles not fit:
Young Older Blind
Sample time at which the first measured melatonin value exceeds the threshold of 10 pg/ml DLMOpost-threshold 0 (0%) 6 (30%) 0 (0%)
Interpolated time when the plasma melatonin concentrations crosses the threshold of 10 pg/ml DLMOinterpolated 0 (0%) 6 (30%) 0 (0%)
Calculated time at which melatonin levels exceed 25% of the peak of the fitted curve DLMOn25% 3 (4%) 7 (35%) 1 (10%)
Calculated time at which melatonin levels fall below 25% of the peak of the fitted curve DLMOff25% 3 (4%) 7 (35%) 1 (10%)
Calculated time at which melatonin levels reach the midpoint of the 24-h upcross and downcross 24hMidpoint 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach the 24-h mean level on the rising portion of the curve 24hUpcross 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach the 24-h mean level on the falling portion of the curve 24hDowncross 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach fit peak using a fundamental+one harmonic (F(2)) curve F2Max 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach half-maximum value of F2Maxfit on rising portion of
curve
F2Upcross 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach half-maximum value of F2Maxfit on falling portion of
curve
F2Downcross 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach fit peak using a fundamental+two harmonic (F(3)) curve F3Max 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach half-maximum value of F3Maxfit on rising portion of
curve
F3Upcross 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach half-maximum value of F3Maxfit on falling portion of
curve
F3Downcross 1 (1%) 2 (10%) 0 (0%)
Calculated time at which melatonin levels reach half of fit maximum value of the skewed bimodal cosine
function on rising portion of curve
SkewedUpcross 1 (1%) 1 (5%) 4 (40%)
Calculated time at which melatonin levels reach half of fit maximum value of the skewed bimodal cosine
function on falling portion of curve
SkewedDowncross 1 (1%) 1 (5%) 4 (40%)
Time of melatonin synthesis onset of melatonin as computed from the linear differential equation model Syn-on 0 (0%) 1 (5%) 0 (0%)
Time of melatonin synthesis offset of melatonin as computed from the linear differential equation model Syn-off 0 (0%) 1 (5%) 0 (0%)
doi:10.1371/journal.pone.0033836.t001
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24hDowncross times.
‘‘Curve-fitting methods’’ refer to methods in which a function
was used to fit the entire melatonin profile; threshold-based
estimates were then computed based on the fit function rather
than the raw data. The curve-fitting methods used Fourier series
with either 2 or 3 harmonics: F(2), a fundamental plus second
harmonic (5 parameters total), and F(3), a fundamental plus
second and third harmonic (7 parameters total); or a skewed
bimodal cosine function [16] (6 parameters total). Circadian phase
markers from each of these methods include the fit maximum
(F2Max, F3Max) and the upcross (F2Upcross, F3Upcross,
SkewedUpcross) and downcross (F2Downcross, F3Downcross,
SkewedDowncross). The Upcross and the Downcross were
computed as the interpolated values at which half the fit maximum
was reached on the rising and falling portion of the curve,
respectively. Data were fit using the lsqnonlin function in MatLab
v.7.3 (MathWorks, Natick MA) and only data for which the model
converged to a solution were included in the analysis.
The differential equation method for analyzing melatonin
rhythms was originally described by Brown et al. [15] and revised
by St. Hilaire and colleagues to incorporate the effect of ocular
light exposure [6]. There are nine parameters that can be fit for
the linear differential equation model; these were fit using the
lsqnonlin function in MatLab v7.3 and only data for which the
model converged to a solution were included in the analysis. Two
of the markers calculated by the model were used for this analysis:
Syn-on, representing the time of melatonin synthesis onset in the
pineal gland, and Syn-off, for the time of synthesis cessation.
In summary, data were available from 98 subjects (67 young
sighted, 20 older sighted, 11 blind). In each subject, the melatonin
profiles were analyzed to generate 17 different circadian phase
estimates on each of three 24-h data segments.
Analyses
To test whether circadian phase drifted uniformly with a linear
relationship across the three 24-h intervals that were assessed, we
examined curvature for each subject using the 24hUpcross and
DLMOinterpolated methods. To test curvature, a paired t-test was
used to compare the slope of the line between phase markers on
days 1 and 2, versus the slope of the line between days 2 and 3. For
each of the six data sets taken from different studies, there was no
curvature, which allowed us to correct for variability associated
with circadian drift (see below).
Variability for each method was determined using two
approaches. In the ‘With Drift’ approach, which represents the
raw data analysis, we found the standard deviation of the clock
hour of the estimate for each phase marker, assessed in each
subject over the three data collection days. However, one potential
source of variability between individuals in phase estimates is
introduced by drift from an endogenous circadian period not
equal to 24.00 (on average 24.15 h that differs between individuals
[25]). To remove this potential source of variability, we first fit a
line through the phase estimates computed for each marker for
each subject for three consecutive days. The non-zero slope of this
fit line represents the amount of drift due to (presumed)
endogenous period. This fit line was subtracted from the estimates
leaving the residuals of the estimates, with zero slope. The
standard error was computed from the residuals of the
estimates (i.e., standard deviation of the residuals).
The variability measure for each method was not normally
distributed; the data were right skewed (with proportionally larger
variability). Therefore, the data were log-transformed before all
further analyses were performed to normalize the data. Linear
regression models and linear mixed-effects models were used to
compare different analysis methods of melatonin, with study being
the random effect and age-group and sex being covariates. All tests
were two-sided with alpha at the 0.05 level.
We calculated the amplitude of each melatonin curve using
non-orthogonal spectral analysis (NOSA) [24], to test whether the
amplitude of the melatonin rhythm affected the phase results.
Amplitude was computed for the CR day (Studies 1–4) or the first
forced desynchrony day (Studies 5 and 6).
We compared the goodness of fit of the different methods using
Adjusted-R
2, which accounts for the number of parameters used in
fitting each model. Adjusted-R
2 can only be calculated for curve
fitting methods, such as F(2), F(3), Skewed and the linear
differential equation model. An Adjusted-R
2 value closer to 1.0
indicates a better fit.
To compare the robustness of the various methods under
conditions of missing data, we selected 5 subjects at random for
whom a complete data set was available and generated a series of
missing data sets for each of them by removing 2 hours of
consecutive data points at every 2-h time window. Four of the
seventeen measures were computed for each missing data set for
each subject (DLMOpost-threshold, DLMOinterpolated, F2Up-
cross, and Syn-on) and compared to these melatonin estimates
obtained from the complete data set. These four methods were
chosen because one was based on the actual sample time
(DLMOpost-threshold), one was based on an interpolated
threshold (DLMOinterpolated), one was based on a curve-fitting
method (F2Upcross) and one was based on a differential equation
method (Syn-on). These were used to determine the effect of
2 hours of missing data at different locations on the melatonin
curve. The location of the data gaps within each pulse were
recorded relative to the DLMOpost-threshold for each subject,
computed from the complete data set. This approach normalizes
the location of the data gaps for each subject to allow comparison
between subjects and to identify the regions in the melatonin
profile most susceptible to missing data.
Results
Not all subjects’ data could be fit with all the methods (Table 1).
If the data could not be fit, then there was either no phase
assessment produced by the analysis program because the method
did not converge to a solution (for curve fitting and differential
equation methods) or the phase assessment using that method was
not physiologically possible. The differential equation methods
had the most fits and the DLMO based methods had the fewest.
There were significantly fewer fits of the data from the older
subjects. The data sets that could not be fit by a method had
significantly smaller amplitudes than the data sets that could be fit
(63.5657.3 (s.d.) vs. 129.7675.5 pmol/L; p,0.001 by t-test),
although there was overlap in the range of amplitudes of those that
could not and those that could be fit by analysis methods (range
6.4–226.5 vs. 38.2–344.0 pmol/L, respectively).
Variabilities
By study. When data were fit without first removing
circadian drift, there were significant differences (P,0.05) in
calculated variabilities between the six study groups using all but
one melatonin method (Syn-off). Therefore, the study conditions
or the different subjects in those studies affected the melatonin
phase estimates when raw (with drift) phase estimates were used.
When drift was removed, however, no significant differences in
calculated variability among the six study groups were found.
Figure 2A contains scatter plots of the variability with drift
Conditions Influencing Melatonin Circadian Phase
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large and the subject with the most variation in one method does
not necessarily have the most variation in another method. There
were statistical significant differences by age in the DLMOinter-
polated method (P=0.0297) and in the 24hDowncross method
(P=0.0445) with older subjects having higher values, and by sex in
the 24hDowncross method (P=0.0008) with female subjects
having lower values in the variability for the three methods tested
(Figure 2B); therefore to adjust for the differences among study
groups, age groups and sex, study was treated as a random effect in
all analyses and age group and sex were treated as covariates when
the data from all the studies were combined.
By method. The raw variabilities (with drift) of the 17 phase
estimates differed significantly between methods (Figure 3,
P,0.0001). The relative variability of these methods was high.
Of the 17 phase estimates used, Syn-off was significantly more
variable than all other methods (P,0.0001). In general, markers
on the falling portion of the curve (e.g. downcross) were more
variable than markers on the rising portion of the curve (e.g.
upcross) (P=0.0003).
When variability was corrected for drift (‘‘drift removed’’) across
three days of data collection, individual variabilities were ,10
times smaller than their respective raw variabilities. The
variabilities of the upward/onset melatonin phase methods were
not significantly different from each other (P=0.57). The
variabilities of all but 4 methods (DLMOpost_threshold, F3Down-
cross, SkewedUpcross and SkewedDowncross) were significantly
smaller than those of the Syn-off method (P,0.05) (Figure 3).
There was no relationship between the fit melatonin amplitude
and the DLMOn25% variability by Pearson correlation (correla-
tion=20.04 [N.S] for ‘With drift’ and correlation=0.04 [N.S]
with ‘Drift removed’). There was no relationship between the
duration of melatonin secretion, calculated as the time between
DLMOn25% and DLMOff25% and the DLMOn25% variability
(Pearson correlation=20.08 [N.S]).
Goodness of fit and missing data
There was no difference among measures when Adjusted-R
2
was calculated for the curve-fitting methods (F(2), F(3), Skewed,
and the linear differential equation model) as a measure of the
goodness of fit (Figure 4). The outliers, with Adjusted-R
2 values
of ,0.2, for each method were from different subjects, supporting
the hypothesis that each method summarizes different aspects of
each data set.
When points were removed from data sets for all methods,
missing data had the strongest effect on phase estimates when the
midpoint of the missing data fell in the 62 hour range of the
DLMOpost-threshold estimate (t=0) from the complete data set
(Figure 5). For both the Syn-on and the DLMOinterpolated
values, missing data resulted in an estimated phase that was earlier
(negative change in the new estimate compared to original) than
the estimated phase from the complete data set in all subjects. For
the DLMOpost-threshold, missing data resulted in a later
estimated phase in all subjects relative to the estimate from
complete data. The direction of change was variable for the
F2Upcross; in most subjects, the phase estimate was earlier when
missing data occurred prior to t=0, and later when the missing
data gap fell after t=0. The magnitude of differences in phase
estimates was greatest for the Syn-on estimate and for the
DLMOpost-threshold estimates. In almost all cases, missing data
that occurred more than two hours away from t=0 had no effect.
The exception was the phase estimate in one subject computed
using Syn-on, which was affected by the missing data when the
midpoint of this missing data was greater than 2 hours after t=0.
In this case, the missing data between the Syn-on and Syn-Off
times affected the fit of the infusion and clearance rate parameters;
because Syn-on is fit simultaneously with infusion and clearance,
changes in these rates also affected the model-predicted Syn-on
times.
Discussion
Our results suggest that when there is a complete data set and
the circadian drift for multi-day data is adjusted, there is no
significant difference between the analysis methods used for
determining melatonin secretion onset or midpoint of secretion.
The studies used in this analysis minimized or eliminated many
sources of noise known to affect melatonin phase estimates
including light, posture, and ambient temperature [7]. Circadian
drift, presumably from each individual’s endogenous circadian
free-running non-24-hr period, was found to be a major source of
variability in melatonin phase estimates computed over consecu-
tive days. When circadian drift is removed, methods measuring the
offset of melatonin are more variable than methods measuring its
onset, and therefore measures of offset should be avoided where
possible. When drift is not removed, as is the case in many
published studies that use melatonin phase estimates to compute
circadian phase resetting, there are differences in variabilities
among the methods.
Various factors such as experimental conditions, analyses methods,
completeness of data (including the relative timing of the missing data)
and participant characteristics (e.g. age) affected the circadian phase
estimates from the melatonin data. The ability to fit the data also
differed among methods, with some methods generating phase
estimates for a given subject and others failing to do so. A method
which is best able to fit many sources of data would be preferable, so
that data sets and sources can be compared, but this study was unable
to determine which method would be ideal. Researchers and
clinicians should consider this evidence when choosing the method
for analyzing melatonin for circadian phase information. It was
assumed that other sources of variability, including those due to
collection and assay, were similar across conditions.
Our finding that offset methods were more variable than onset
and midpoint methods is in contrast to two previous analyses, one
which found no difference in the variability of onset and offset
methods [1] and one in which offset methods were found to
provide more stable estimates of phase compared to onset and
midpoint methods [17]. One possible explanation is the difference
in study conditions between the present and former analyses. In
Klerman et al. [1], all phase estimates (onsets and offsets) were
measured from melatonin profiles collected during constant
routine conditions in which subjects were awake in dim light. In
Benloucif et al. [17], melatonin was assessed while subjects
maintained a habitual sleep-wake schedule. Presumably, in this
latter study, the falling portion of the curve occurred during the
subject’s habitual sleep episode, and therefore melatonin offsets
may have been masked during sleep. In the present study, the
analysis over three consecutive days included both baseline days in
which subjects maintained a habitual sleep-wake schedule and
constant routine days. One source of variability in the current
analyses’ melatonin offsets therefore may be due to unmasking of
melatonin offsets during the constant routine days. This mixture of
habitual sleep-wake and constant routine days would presumably
not have an effect on onset variability because the rising portion of
the curve is more likely to occur prior to habitual sleep onset,
meaning that across three consecutive days onsets would always be
assessed in dim light during wake. In addition, the physiology
underlying melatonin offset is unclear and may be due to multiple
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e33836Figure 2. A. Variability by Study With Drift and Drift Removed. Box plots of the variability with and without drift of three circadian phase
assessment methods by study. Note difference in y-axis scales between With Drift and Drift Removed. The Box plots show Maximum, Mean,
Minimum, and Percentiles 99, 75, 50, 25, and 1 of the data. Figure 2B. Variability by age group and sex. Scatter plots of each subject’s variability
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33836(with drift removed) of three of the methods using data from all subjects. Also indicated as (#not fit) is the number of subjects for whom that
method did not yield a phase estimate.
doi:10.1371/journal.pone.0033836.g002
Figure 3. Variability of all methods With Drift and Drift Removed. The Box plots show Maximum, Mean, Minimum, and Percentiles 99, 75, 50,
25, and 1 of the data from all subjects. Black are onset methods, red are offset methods, and blue are maximum or midpoint methods. Note
difference in y-axis scales between With Drift and Drift Removed.
doi:10.1371/journal.pone.0033836.g003
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e33836Figure 4. Goodness of fit using Adjusted-R
2 for four curve-fitting methods. The Box plots show Maximum, Mean, Minimum, and Percentiles
99, 75, 50, 25, and 1 of the data from all subjects using the four curve-fitting methods: F(2), F(3), Skewed and Physiological.
doi:10.1371/journal.pone.0033836.g004
Figure 5. Change in phase estimates (hours) for subjects with 2-hour gaps of data. Change in phase estimates for simulations of 2-hour
missing data at different times relative to the melatonin phase marker for five subjects total from Studies 1, 2 and 3. Each panel plots the change in
phase estimates for a different method. Data gaps are referenced as the time of midpoint of each gap relative to the DLMOpost-threshold computed
from the complete data set for each subject. Positive changes in phase estimate indicate that the estimated phase from the missing data set is later
relative to the estimate from the complete data set, while negative values indicate that the estimate from the missing data set was earlier.
doi:10.1371/journal.pone.0033836.g005
Conditions Influencing Melatonin Circadian Phase
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e33836factors, including the end of synthesis of melatonin and clearance
of melatonin already circulating; it is difficult to mathematically
determine the end of synthesis alone because these processes
overlap in time.
For data sets with missing data, the location of the gap is crucial
in determining the effect of the gap on phase estimate. All methods
are most susceptible to gaps within two hours of the estimate
determined from the complete data set, although the direction of
the shift in phase estimate (earlier or later relative to the estimate
obtained from the complete data set) varies between methods.
Extra attention should be given to data from subjects with missing
data in this range, and since the true phase is not known,
appropriate adjustments cannot be made. Visual observation is
crucial in verifying that the fit and marker estimates generated by
the method are plausible, although such techniques are insufficient
for determining the correct phase estimate. The finding that the
greatest differences observed in phase shifts in response to missing
data were for phase estimates of the linear differential equation
model and the DLMOpost-threshold and the least for F2Upcross
corroborates Klerman et al. [1], who hypothesized that curve-
fitting models are more flexible than threshold-based methods.
Our results show that for data sets with missing data, especially
near the expected onset of melatonin secretion, curve-fitting
procedures may be much better than threshold-based procedures
at generating an accurate circadian phase assessment. Not all
studies, however, collect melatonin samples throughout the entire
secretory episode, and therefore curve-fitting methods cannot be
used under these circumstances.
An analysis by Van Someren and Nagtegaal (2007) similarly
found that missing data affects the phase estimate using a method
in which they eliminated 4 random data points from 24 hourly
samples, rather than 4 consecutive data points as was done in the
present analysis. They proposed a sparse-sampling schedule with
11 of 24 data points across the 24-hr day with increased sampling
clustered around expected onset and offsets; this schedule suggests
that the most important sampling window for robust phase
estimates of onset occurs around the expected onset, although
their analysis did not systematically test this. Their analysis also
does not indicate the direction of the effect on phase estimate, an
effect which may be crucial when interpreting the magnitude of a
phase shift as a delay or advance.
The drift in circadian phase independent of the experimental
intervention (e.g., due to the intrinsic period of the circadian
pacemaker) should be considered when interpreting results. The
larger variability encountered when applying methods to raw data
demonstrates the importance of an analysis which properly
compensates for the circadian drift (which is related to intrinsic
circadian period of an individual) across days. Additional, slow
changes could occur in the melatonin profile parameters over
multiple days that would contribute to the variability. The
calculation used in this study to estimate variability while
accounting for drift is relatively simple, but it requires three or
more days of data. In the case of isolated or missing data, it is
impossible to use this analysis to compensate properly for the drift.
Unfortunately, the variabilities for the method cannot be
converted to variability for a single sample because the current
analyses were based on methods and not on individuals.
Therefore, we can not calculate the statistical error in the
melatonin phase estimate of a single subject for a single day for
the different methods.
The choice of method or marker for an analysis of melatonin
data depends on many factors. Our analysis suggests that the most
robust phase estimates will be obtained using any of the methods
looking at melatonin estimates on the rising portion of the curve
provided that at least 3 complete melatonin profiles are collected
over consecutive days in dim light in order to adjust for drift; Syn-
on has the additional advantage of being relevant physiologically.
When these conditions cannot be met to remove drift, some
methods may be more accurate depending on the amount of data
that can be collected.
Our analysis did not systematically evaluate the robustness of
the measures in the presence of noise other than that due to
intrinsic drift. An analysis by Van Someren and Nagtegaal (2007)
reported the robustness of each phase estimate to added noise by
multiplying each data point by a variable randomly selected
between 0.8 and 1.2. Thus, although we know which methods are
more robust in the presence of this noise, we do not know the form
of this noise. Our analysis instead assumes that such noise is
already present in the data due to collection or assay; noise due to
other factors such as light, posture and ambient temperature was
minimized in most of the studies used here, but not necessarily in
other facilities. We do not know, however, the statistical
distribution of this noise and we assume that the statistical
distribution is consistent across days within a subject and
consistent across subjects.
Our analyses suggest that all precautions should be taken to
prevent missing data in the 2-hour window before and after
expected onset. It is impossible to know a priori where the onset of
melatonin will occur, particularly if the experimental protocol
includes an intervention that alters circadian phase, and therefore
at least one complete melatonin profile is necessary to establish the
window during which melatonin samples should be taken in order
to avoid errors in phase estimates due to poor sampling. This is
especially true in the clinical setting in which patients with
circadian rhythm disorders may have melatonin onsets occurring
outside of the expected window.
As no differences were found in the variability of phase
estimates in subjects with a low amplitude melatonin rhythm, we
hypothesize that our findings will be applicable for salivary
melatonin samples, which have lower concentrations than plasma
samples, although saliva is rarely collected uninterrupted for
multiple days. The ability of a method to fit the data, especially if
the data are low amplitude or have missing samples, is also
important. Since melatonin phase is used for diagnosis and
treatment of circadian disorders and for timing experimental
interventions, the choice of analysis method may potentially
influence results. Therefore, careful consideration of the subject
characteristics, the study conditions and the ability to collect
complete data sets are vital.
Melatonin can be an accurate marker of human circadian
pacemaker phase with appropriate application of analysis methods
to datasets and experimental conditions. Even under such
conditions, in the presence of missing data or low amplitude
rhythms, the choice of melatonin analysis method may affect the
result obtained. Variability in phase estimates was significantly
lower when drift associated with free-running circadian rhythms
was removed and when a complete melatonin profile was
available. Given that such conditions may not be always available,
comparison of markers revealed that those based on the detection
of a time during rising melatonin concentrations were similar in
their variability and therefore are recommended for use.
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